Brands

<h2 dir="ltr">What Are Mutation Detection Kits?</h2>
 Mutation detection kits confirm that CRISPR/Cas9 (or TALEN/ZFN) editing has produced the intended insertions or deletions (indels) before researchers proceed to downstream experiments. Enzymatic mismatch cleavage (EMC) assays, primarily T7 endonuclease I (T7E1) and Surveyor nuclease, are the most widely adopted method due to their simplicity and compatibility with standard molecular biology infrastructure. Reliable mutation detection is essential for confirming genetic variants and genome-editing outcomes. Select the kit that aligns with your analytical requirements.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" aria-level="1">
Genomic Cleavage Detection Assays: Specialized kits designed to quantify indel frequency via T7E1 or Surveyor nuclease-mediated mismatch recognition.
</li>
<li dir="ltr" aria-level="1">
Screen It&trade; CRISPR Cas9 Systems: High-throughput compatible tools for streamlined validation of locus-specific modifications with minimal sequence bias.
</li>
</ul>
<h2 dir="ltr"> How to Choose a Mutation Detection Kit</h2>
 Mutation Type T7E1 offers higher sensitivity for insertions and deletions (indels), making it the preferred first-line tool for confirming CRISPR knockout experiments. Surveyor nuclease performs better for single-nucleotide substitutions. Required Resolution EMC assays (T7E1, Surveyor) serve as rapid, cost-effective screening tools, typically detecting indel frequencies down to 2&ndash;5% in a mixed population. For more precise quantification at lower frequencies, NGS-based methods such as TIDE or targeted amplicon sequencing are recommended. Equipment Available T7E1 and Surveyor assays require only a thermal cycler, standard PCR reagents, agarose gel electrophoresis equipment, and a UV transilluminator &mdash; all standard in most molecular biology labs, with no specialised equipment needed. Editing Technology Compatibility Mutation detection kits in MBP's catalogue are compatible with CRISPR/Cas9 (all Cas9 variants), CRISPR/Cas12 systems, TALENs, and zinc finger nucleases (ZFNs), as well as a range of model organisms beyond mammalian cell lines. Throughput Needs PCR-based mutation detection assays run in parallel across many samples in a single thermal cycler run, making them well-suited to high-throughput clone screening after bulk editing confirmation. 
<h2 dir="ltr"> Specifications Context</h2>
 The T7E1 workflow involves four steps: PCR amplification of the target region, denaturation and re-annealing to form heteroduplexes, enzymatic digestion with T7E1 (which cleaves mismatched DNA), and gel analysis, where the ratio of cut to uncut bands estimates editing efficiency. Research published in G3: Genes|Genomes|Genetics shows T7E1 outperforms Surveyor for detecting deletions, while Surveyor has advantages for point mutations. A positive T7E1 result confirms indel presence but not the exact sequence; Sanger sequencing or targeted NGS typically follows to characterise the edit. Running a known-positive control alongside experimental samples -- for example, a previously validated guide RNA targeting the same locus -- helps confirm the T7E1 digestion conditions are working correctly before interpreting negative results as a failed edit. Product availability reflects MBP's catalogue as of mid-2026. 
Contact the <a href="https://mbpinc.net/contact-us" style="color: #236fa1;">expert team at MBP Inc</a>. today to request a quote for the right mutation detection kit for your lab.

Mutation Detection Kits

DataSheet

CRISPR Genomic Cleavage Detection Kit

Unit Quantity

Storage Condition

Shipping Condition

<h2 dir="ltr"> What Are AAV CRISPR/Cas9 Negative Controls?</h2>
 AAV-delivered CRISPR/Cas9 is the dominant platform for in vivo gene editing in pre-clinical research. Matched negative controls are mandatory for valid interpretation of in vivo editing experiments because AAV transduction, Cas9 expression, and sgRNA processing each independently affect transduced cells regardless of target specificity. The right CRISPR/Cas9 control is essential for distinguishing editing effects from delivery and background responses. Select a control system appropriate for your genome editing workflow.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" role="presentation">SpCas9&nbsp; sgRNA AAV viruses control (serotypes 1&ndash;11) for Streptococcus pyogenes Cas9 experiments.</li>
<li dir="ltr" role="presentation">SaCas9 Scrambled sgRNA viruses control for the smaller Staphylococcus aureus Cas9 nuclease.</li>
<li dir="ltr" role="presentation">All-in-One AAV Control Vectors contain both a non-targeting scrambled sgRNA and saCas9&nbsp;&nbsp;</li>
<li dir="ltr" role="presentation">Non-Viral CRISPR Control Plasmids used in transient transfection studies for scrambled sgRNA expression&nbsp;</li>
<li dir="ltr" role="presentation">Ampicillin-Resistant AAV Backbones for stable cloning and propagation.&nbsp;</li>
<li dir="ltr" role="presentation">Serotype-Specific All-in-One Virions as a negative control for tissue-specific assessment</li>
</ul>
<h2 dir="ltr"> How to Choose an AAV CRISPR/Cas9 Control</h2>
 Cas9 Orthologue Matching Controls should match the Cas9 orthologue used experimentally &mdash; SpCas9 or the more compact SaCas9 (relevant for single-AAV delivery within the ~4.7 kb packaging limit). Non-Targeting sgRNA Validation As with other CRISPR delivery formats, non-targeting (not scrambled) sgRNAs bioinformatically verified against PAM-adjacent genomic sites are required to avoid unintended editing in the control group. Cas9-Inclusive vs. sgRNA-Only Format A non-targeting sgRNA + Cas9 AAV construct controls for the full system; an sgRNA-only (no Cas9) AAV construct isolates the contribution of guide RNA delivery alone. Serotype Matching for In Vivo Work The control AAV should match the serotype of the experimental construct to ensure equivalent tissue tropism and transduction efficiency in vivo. Split-Vector System Considerations For split-vector AAV-CRISPR systems (Cas9 and sgRNA on separate AAV particles), the control should replicate the same two-vector delivery approach. 
<h2 dir="ltr"> Specifications Context</h2>
&nbsp;
AAV delivery can activate innate immune pathways, while Cas9 expression may induce cellular stress and DNA damage responses. sgRNA is expressed in all transduced cells regardless of targeting sequence, making matched controls essential to distinguish on-target editing effects from vector- and CRISPR-related background activity. SaCas9 (~3.2 kb) is smaller than SpCas9 (~4.2 kb) and is often used for single-AAV delivery; controls should match the Cas9 orthologue used. Non-targeting sgRNA AAV controls &mdash; with and without Cas9 &mdash; are available from ABM (Applied Biological Materials) for both SpCas9 and SaCas9 systems. As with other AAV systems, matched production batches help reduce titer-related variability, and serotype-dependent transduction should be confirmed before in vivo studies due to differences in tissue tropism.
&nbsp;
<a href="https://mbpinc.net/contact-us" style="color: #236fa1;">Contact the expert team </a>at MBP to get high-quality CRISPR control for your next successful experiment.